Literature DB >> 8458244

In vitro activity of levofloxacin, ofloxacin and other quinolones against coagulase-negative staphylococci.

B D Foleno1, S C Lafredo, K P Fu.   

Abstract

The in vitro activity of levofloxacin against coagulase-negative staphylococci (CNS) was investigated. In vitro, on the basis of MIC90 values, levofloxacin was as active as ciprofloxacin, inhibiting both methicillin-sensitive and -resistant staphylococci at 0.5 microgram/ml. The frequency of one-step development of levofloxacin-resistant CNS was < 1 x 10(-9). After repeated transfer of CNS in the presence of increasing concentrations of levofloxacin or other quinolones, there were 4-fold increases in MIC50 values for both levofloxacin and ofloxacin, whereas there were 64- to 128-fold increases for ciprofloxacin, norfloxacin and enoxacin. Based on MIC50 values, the concentrations of 1 or 2 micrograms/ml are clinically relevant. The mutant strains induced by levofloxacin showed less virulence based on the LD50 value in acute systemic murine infection.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8458244     DOI: 10.1159/000239112

Source DB:  PubMed          Journal:  Chemotherapy        ISSN: 0009-3157            Impact factor:   2.544


  4 in total

Review 1.  Enoxacin: a reappraisal of its clinical efficacy in the treatment of genitourinary tract infections.

Authors:  S S Patel; C M Spencer
Journal:  Drugs       Date:  1996-01       Impact factor: 9.546

2.  Prevalence of resistance to three fluoroquinolones: assessment of levofloxacin disk test error rates and surrogate predictors of levofloxacin susceptibility. AST Surveillance Group.

Authors:  P C Fuchs; A L Barry; S D Brown
Journal:  Antimicrob Agents Chemother       Date:  1996-07       Impact factor: 5.191

3.  Comparative prophylactic efficacies of ciprofloxacin, ofloxacin, cefazolin, and vancomycin in experimental model of staphylococcal wound infection.

Authors:  D S Kernodle; A B Kaiser
Journal:  Antimicrob Agents Chemother       Date:  1994-06       Impact factor: 5.191

Review 4.  Levofloxacin. A review of its antibacterial activity, pharmacokinetics and therapeutic efficacy.

Authors:  R Davis; H M Bryson
Journal:  Drugs       Date:  1994-04       Impact factor: 9.546

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.